Vicapsys Life Sciences (VICP) 10-Q2022 Q1 Quarterly report

Filed: 13 May 22, 5:10pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. junior Avg

New words: advice, Advisory, Affiliate, Alpha, announced, assistance, attributable, cadaveric, China, Codification, congregating, country, credited, Delta, diabetic, diligence, Donohoe, economy, eighteen, elapsed, emergence, emergency, entirety, equivalent, Europe, evolving, exhausted, exposure, FASB, hundred, IR, Japan, laboratory, leading, level, listing, LLC, longer, low, manufacturing, minimum, monthly, NaN, NASDAQ, national, Omicron, people, Phase, platform, policy, primate, quarantining, ratio, recovery, retrospectively, SCHEDULE, sixteen, slight, stability, Standard, Sublicensee, thirteen, thousand, Toneguzzo, travel, treasury, trial, unknown, variant, wake, warrant, xi, xii, xiii, xiv, xv, xvi, xvii, xviii

Removed: academic, agreeing, alternative, aspect, biology, closely, combat, daily, decision, deck, deemed, delay, depend, directly, Dr, end, excused, extending, facilitate, federal, finance, focusing, formation, fund, fundraising, governmental, healing, hindered, human, incorporating, increasing, indirectly, intended, justification, lab, largely, led, liability, local, long, milestone, minimizing, mitigation, monitoring, negotiating, ninety, option, passed, percent, pitch, planning, preclude, prediction, prolonged, protect, pursuing, range, recommended, relevant, renewed, reopen, restate, restrict, satisfying, Security, significantly, situation, SPA, substantially, ultimate, variety, vested, wound

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

VICP similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND

CHIEF FINANCIAL OFFICER PURSUANT TO RULE 13a-14(b) UNDER

THE SECURITIES EXCHANGE ACT OF 1934 AND SECTION 1350 OF

CHAPTER 63 OF TITLE 18 OF THE UNITED STATES CODE

Each of the undersigned, Federico Pier and Jeffery Wright, certifies pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934 and Section 1350 of Chapter 63 of Title 18 of the United States Code, that (1) this quarterly report on Form 10-Q for the quarter ended March 31, 2022, of Vicapsys Life Sciences, Inc. (the “Company”) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934, and (2) the information contained in this report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 13, 2022

	/s/ Federico Pier
	Federico Pier,
	Chief Executive Officer and Executive Chairman of the Board (principal executive officer)

	/s/ Jeffery Wright
	Jeffery Wright,
	Chief Financial Officer (principal financial officer)

This certification accompanies this Quarterly Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.